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Abstract
Background: In predicted severe acute pancreatitis, infections have a negative effect on clinical outcome. A start
of enteral nutrition (EN) within 24 hours of onset may reduce the number of infections as compared to the current
practice of starting an oral diet and EN if necessary at 3-4 days after admission.
Methods/Design: The PYTHON trial is a randomised controlled, parallel-group, superiority multicenter trial. Patients
with predicted severe acute pancreatitis (Imrie-score ≥ 3 or APACHE-II score ≥ 8 or CRP > 150 mg/L) will be
randomised to EN within 24 hours or an oral diet and EN if necessary, after 72 hours after hospital admission.
During a 3-year period, 208 patients will be enrolled from 20 hospitals of the Dutch Pancreatitis Study Group. The
primary endpoint is a composite of mortality or infections (bacteraemia, infected pancreatic or peripancreatic
necrosis, pneumonia) during hospital stay or within 6 months following randomisation. Secondary endpoints
include other major morbidity (e.g. new onset organ failure, need for intervention), intolerance of enteral feeding
and total costs from a societal perspective.
Discussion: The PYTHON trial is designed to show that a very early (< 24 h) start of EN reduces the combined
endpoint of mortality or infections as compared to the current practice of an oral diet and EN if necessary at
around 72 hours after admission for predicted severe acute pancreatitis.
Trial Registration: ISRCTN: ISRCTN18170985
Background
In 20% of patients, acute pancreatitis is complicated with
peripancreatic and pancreatic necrosis [1]. In about 30% of
these patients, this necrotic tissue becomes infected and
this is associated with a mortality rate of approximately
15% [2,3]. In addition to infected necrosis, other infections
such as bacteraemia and pneumonia frequently occur with
a major negative impact on outcome [4,5]. Attempts to
reduce infections with the prophylactic use of antibiotics
were unsuccessful [6,7]. The current hypothesis is that
these infections originate from the gut. Gut-derived
bacteria translocate due to a combination of pathophysio-
logical events - disturbed gastrointestinal motility, bacterial
overgrowth, reduction of arterial blood flow, increased
permeability of the gastrointestinal mucosal barrier and
bacterial translocation - leading to distant systemic infec-
tions, including infection of peripancreatic or pancreatic
necrosis [8-11]. These phenomena already occur within a
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few hours after onset of symptoms and cause early infec-
tions [12-14]. This implies that there is only a very narrow
time-window for reducing bacterial translocation and sub-
sequent infections [5]. In clinical practice, patients with
predicted severe acute pancreatitis are generally kept at a
‘nil per mouth’ regimen until the disease severity becomes
clear. After a few days, some patients can start an oral diet
while others require a nasojejunal catheter for enteral
nutrition. This usually takes 3 to 4 days and the deleter-
ious effects on the gastrointestinal tract already have taken
place [1].
Enteral nutrition (EN) has the ability to maintain gut
integrity, stimulate gut contractility and the release of
immunomodulating agents and blood flow to the gut
[15]. The maintenance of blood flow, preserved motility
and gut mucosal integrity theoretically reduce bacterial
overgrowth and bacterial translocation and thereby
potentially reduces the number of infections. Further-
more, maintaining mucosal integrity reduces the release
of inflammatory mediators, decreases oxidative stress and
abates the systemic inflammatory response syndrome
(SIRS) [16]. EN has already proven superior to parenteral
nutrition in reducing mortality and infections in pre-
dicted severe pancreatitis [17]. In intensive care patients
with other diseases, a meta-analysis of randomised trials
demonstrated a reduction of infections following a very
early start of enteral nutrition [18]. A 2009 systematic
review suggested that also in patients with acute pancrea-
titis a very early start of EN improves outcome [19].
The PYTHON trial was designed to investigate
whether a start of EN within 24 hours after admission
counteracts the early deleterious effect of SIRS on bowel
mucosa and reduces infections and mortality in predicted
severe acute pancreatitis, as compared to a start of EN
after 72 hours.
Methods
Design
The PYTHON trial is a randomised controlled, parallel-
group, superiority multicenter trial. Patients will be ran-
domly allocated to receive EN within 24 hours through
a nasojejunal catheter or start after 72 hours of admis-
sion with an oral diet if tolerated or EN through a naso-
jejunal catheter if necessary. Patients with a primary
episode of predicted severe acute pancreatitis are eligible
for randomization.
The aim of the study is to investigate whether the clini-
cal outcome can be improved by a very early start of EN,
as compared to the current practice of an oral diet and
EN if necessary, i.e. at around 72 hours after admission.
Primary endpoint
The primary endpoint is a composite of mortality or
infections (i.e. bacteraemia, pneumonia and infected
necrosis; see Table 1 for definitions) occurring during
hospital admission or within 6 months following rando-
misation. Re-admission within 10 days after initial hospi-
tal discharge is considered part of the index admission.
Secondary endpoints
Attenuation of the acute inflammatory response is
hypothesized to be part of the beneficial effect of very
early feeding on outcome thus secondary endpoints to
assess such an effect are:
• Daily APACHE-II scores (see Additional file 1;
Table S3), SIRS (presence, onset, duration, see Addi-
tional file 1; Table S4), CRP, and white cell count
during the first week following randomisation.
• The individual components of the primary end-
point, need for and number of interventions (percu-
taneous or endoscopic transgastric drainage, surgical
or endoscopic necrosectomy, other operations), use
of antibiotics, length of hospital stay and in-hospital
mortality.
• New onset organ failure (single or multi-system
organ failure, timing and duration of failure), daily
Marshall scores and need for and duration of ICU
admission at any time during follow-up (for defini-
tions see Additional File 1; Table S1 and Table S2).
Other secondary outcome measures are:
• The presence of peripancreatic and pancreatic
necrosis on contrast enhanced computed tomogra-
phy (CT) and the CT Severity Index (CTSI) as mea-
sured 5-7 days after admission. Peripancreatic
necrosis (only) is defined as persistent peripancreatic
fluid collections on a CT performed more than
14 days after admission in the absence of pancreatic
parenchymal necrosis.
• Abdominal pain as daily measured by the Visual
Analogue Scale (VAS).
Table 1 Primary endpoint: definition of infections
Infection Definition
Infected pancreatic
necrosis
Positive culture of pancreatic or peripancreatic
necrotic tissue obtained by means of fine-needle
aspiration or from the first drainage procedure or
operation, or the presence of gas in the fluid
collection on contrast-enhanced CT.
Bacteraemia Positive blood culture. For non-pathogens (eg.
coagulase negative staphylococci) at least 2
samples have to be positive.
Pneumonia Coughing or dyspnoea, radiography with
infiltrative abnormalities, raised inflammatory
variables and positive sputum culture. On the
intensive care unit a positive endotracheal culture
is mandatory.
Bakker et al. Trials 2011, 12:73
http://www.trialsjournal.com/content/12/1/73
Page 2 of 9
• Proportion of daily nutritional target achieved at 1
week after admission.
• Nutrition related complications: diarrhea, aspira-
tion pneumonia, need for conversion from EN to
PN or additional PN and need for replacement of
nasojejunal feeding tube after dislocation.
• Number of days until intake of solid food.
• Number of patients without the need for tube
feeding in the selective delayed EN Group.
• Proportion of cross-over between both study arms.
• Hand grip muscular strength measured by the
Jamar dynamometer.
• Quality of life measured by the EQ5D and SF-36
questionnaires.
• Total direct medical and indirect costs from a socie-
tal perspective during admission and until 6 months
after discharge (details are available in the Additional
File 1).
Study Population
All patients admitted with a first episode of acute pancrea-
titis to one of the 20 participating hospitals of the Dutch
Pancreatitis Study Group (DPSG, hospitals are listed
below) will be assessed for eligibility within 24 hours after
hospital admission. Potential eligible patients are followed
during the first 24 hours after admission until eligibility is
established or the first 24 hours following admission have
passed. If patients are classified as ‘predicted severe’ acute
pancreatitis, they are included and stratified for hospital
and APACHE-II score <13 or ≥13 and randomised in a
1:1 ratio, to receive early EN or an oral diet or EN if neces-
sary at 72 hours after admission (figure 1) [20].
Inclusion criteria
• Diagnosis of acute pancreatitis if at least 2 of the 3
following features are present: 1) upper abdominal
pain, 2) serum lipase or amylase levels above 3 times
the upper level of normal and 3) characteristic find-
ings of acute pancreatitis on cross-sectional abdom-
inal imaging.
• Predicted severe pancreatitis within 24 hours after
admission defined as one or more of the following
(for definitions see Additional File 1; Tables S3
and S5):
- APACHE-II score ≥ 8
- Imrie-score ≥ 3
- CRP level > 150 mg/L
• Age ≥ 18 years
• Written informed consent
Exclusion criteria
• History of acute or chronic pancreatitis
• Identification of patients > 24 hours after
admission
• Onset of symptoms > 96 hours (4 days) before
admission
• Acute pancreatitis due to malignancy or post-
ERCP pancreatitis
• Diagnosis of acute pancreatitis confirmed during
laparotomy for acute abdomen
• Artificial nutrition at admission (EN or PN)
• Pregnancy
Treatment protocol
After the diagnosis has been established, the disease has
been characterized as ‘predicted severe’ and written
informed consent has been obtained, the patient will be
randomised.
Group A: Very early start of EN, i.e. within 24 hours
A nasojejunal feeding tube is placed either endoscopi-
cally or radiologically. If placed endoscopically, an
abdominal X-ray is performed to check the tube’s posi-
tion and in case of radiological placement, fluoroscopy
is used. Nasojejunal placement is considered correct,
when the tip of the tube is placed beyond Treitz’ liga-
ment. After tube placement (figure 2), EN is started
immediately using a very strict volume regimen: 20 ml/h
in the first 24 hours, 45 ml/h, between 24-48 h, 65 ml/h,
between 48-72 hours and, at 72 hours and thereafter:
full nutrition, defined as an energy target of 25 kcal/kg/
day (ICU patients) and 30 kcal/kg/day (non ICU
patients) [21,22].
Group B: oral diet and EN if necessary at 72 hours after
admission
Following randomisation, patients will be kept ‘nil by
mouth’ without any artificial nutrition during the first
72 hours after admission (figure 2). If patients sponta-
neously request for oral food within these 72 hours,
liquid and solid food are offered as requested and toler-
ated (”ad libitum“). If, at 72 hours after admission,
patients develop organ failure, they will receive nasojeju-
nal feeding with the same regimen as in group A. If, at
72 hours, there is no organ failure, patients are offered
oral food ad libitum. If oral food is not tolerated, there
is a re-challenge the next morning and if still not toler-
ated, EN is started through a nasojejunal feeding tube.
General nutrition regimen
At 72 hours after the start of enteral feeding, the nutri-
tional status will be evaluated and in case of intolerance,
the type of EN will be changed accordingly (additional
proteins, calories, fibers etc.). The patient is weighed
twice a week during the first month after randomisation
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and once a week until discharge thereafter. If feeding is
not tolerated EN is reduced to 50% and stepwise rebuilt
gradually until tolerated. If, after two of such attempts,
full nutrition can not be attained, PN will be started to
reach the required energy target. Oral normal feeding is
started, when abdominal pain has resolved and organ
failure has subsided. In case of full tolerance of oral
food nasojejunal feeding is gradually decreased. If pain
relapses, EN is restarted. In case of nausea or vomiting,
lowered consciousness (Glasgow Coma Score [GCS] 14
or lower in a non-intubated patient), or gastric residual
volume (GRV) > 250 ml/6 hours, the position of the
feeding tube is checked (see Additional file 1; figure S1).
Patients in the Intensive Care Unit (ICU)
In case of ICU admission, irrespective of time from
admission, the patient is fed according to the attending
intensivist’s preference (nasogastric or nasojejunal; ent-
eral or parenteral). These patients are analyzed accord-
ing to the treatment assigned.
All adult patients with a first episode of predicted 
severe acute pancreatitis 
Exclusions 
Not meeting inclusion criteria 
    - Predicted mild acute pancreatitis 
Meeting exclusion criteria 
    - History of acute or chronic pancreatitis  
    - Admitted to hospital > 24 hours 
    - Onset of symptoms > 96 hours (4 days) before admission 
    - Other exclusion criteria (post-ERCP pancreatitis) 
Declined to participate 
104 Assigned to very early start of 
enteral nutrition 
100 Received allocated treatment 
4 Received enteral nutrition  
   > 24 hours after randomisation 
104 Assigned to normal start of 
enteral nutrition 
103 Received allocated treatment 
1 Received enteral nutrition  
   < 72 hours after randomisation 
208 patients to be randomised 
1 Lost to follow-up 1 Lost to follow-up 
103 Analyzed 103 Analyzed 
Figure 1 Flow of participants PYTHON trial according to CONSORT.
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General treatment regimen
All patients will undergo contrast enhanced CT within
5-7 days after admission. Intravenous antibiotics are
administered based on culture results and not as prophy-
laxis in case of necrotizing pancreatitis without docu-
mented infection. Invasive intervention for (suspected)
infected necrosis is preferably postponed until the fluid
collections are walled-off and demarcated on CT-scan.
The type of antibiotics administered depends on local
guidelines and is left to the discretion of the attending
physician. ERCP is performed in case of suspected cho-
langitis or in case of biliary pancreatitis with clinically
First 72 h of admission: 
-  Nil per mouth and no artificial nutrition 
-  Exception: patients spontaneously       
                     requesting food 
< 24 h of admission: 
   -  Nasojejunal tube 
   -  Start EN 
Group A 
Very early start of EN 
Group B 
Normal start of EN 
At 72 h of admission: 
Organ failure?  
(cardiovascular/pulmonary/renal) 
Yes No 
Offer food again next 
morning 
If food is 
tolerated
If food is not 
tolerated at 
96 h (4 
days) after 
admission 
  -  Nasojejunal tube 
  -  Start EN 
Increase diet 
ad libitum
Offer hospital food  
(liquid or solid) as preferred 
by patient 
Does patient tolerate this? 
Yes No 
Randomisation
Predicted severe 
pancreatitis 
Figure 2 PYTHON flowchart.
Bakker et al. Trials 2011, 12:73
http://www.trialsjournal.com/content/12/1/73
Page 5 of 9
important persistent cholestasis. Patients can be dis-
charged from hospital once abdominal pain has resolved,
infection variables (leucocytes, CRP) have decreased to
near normal and a normal oral diet is tolerated.
Randomisation
Randomisation is performed centrally by the study coordi-
nator using an internet randomisation module (Julius Cen-
ter for primary care and health sciences, University
Medical Center Utrecht, the Netherlands). Randomisation
is stratified according to the predicted severity of disease
(’predicted moderate severe’ vs. ‘predicted very severe’;
APACHE-II < 13 or ≥ 13) and according to hospital. Per-
muted-block randomisation with varying block size is used
and block size is concealed to all local investigators.
Data collection and follow-up
Follow-up visits will take place at 3 and 6 months after
discharge. Data collection will be performed by local
physicians using a written case-record form. An inde-
pendent auditor will check all primary and secondary
endpoints and at least 10% of data in case-record forms
against on-site source data. Discrepancies detected by
the auditor will be resolved on the basis of consensus by
two investigators unaware of the study-group assign-
ment and not involved in patient care.
Safety
An independent data and safety monitoring committee
(DSMC) will evaluate the progress of the trial and will
examine safety variables after every 25 patients have
completed the 6 months follow-up. This evaluation is
based on unblinded data, in the presence of the study
coordinator as far as the ‘explanatory part’ of the meeting
is concerned. After full explanation of the data presented,
the study coordinator is dismissed and the DSMC dis-
cusses the consequences of the data presented. Adverse
events are defined as ‘any undesirable experience occur-
ring to a subject during a clinical trial, whether or not
considered related to the intervention’ (i.e. early enteral
nutrition). All involved physicians will repetitively be
asked to report any potential adverse events. These
adverse events will be listed and discussed with the
DSMC. The outcome of the meeting of the DSMC will
be discussed with the trial steering committee. The out-
come will also be sent to the Utrecht institutional review
board (IRB). The data of the deceased patients will be
evaluated by the DSMC for cause of death and possible
trial related serious adverse events. All possible adverse
events will be reported to the Central Committee on
Research involving Human Subjects (Centrale Commissie
Mensgebonden Onderzoek [CCMO]) and the IRB using
the online module https://toetsingonline.ccmo.nl
Ethics
The study will be performed in accordance with the
declaration of Helsinki and the Dutch “Wet Medisch-
wetenschappelijk Onderzoek met Mensen” (Medical
Research Involving Human Subjects Act). The IRB of the
University Medical Center Utrecht approved the protocol
on the 4th of March 2008. Secondary approval was sought
from all local ethics committees. Informed consent will be
obtained from each participating patient in oral and writ-
ten form prior to randomisation. The PYTHON trial is
registered in the ISRCTN register with identification num-
ber ISRCTN18170985. After approval of the protocol, 2
amendments were approved by the ethics board. These
amendments followed new regulations in the Netherlands
for the reporting of (serious) adverse events. The content
of both amendments is incorporated in this protocol.
Statistical Aspects
Sample size calculation
The PYTHON trial is a superiority trial, hypothesizing a
reduction in the primary endpoint in favour of early EN as
compared to the current practice of an oral diet and EN, if
necessary at 72 hours after admission. Data from patients
in the PROPATRIA trial are used to calculate sample size
[23]. All patients in the placebo-arm of the PROPATRIA
trial received EN via a nasojejunal feeding tube. Patients
from the PROPATRIA trial that fulfilled the PYTHON
inclusion criteria (predicted severe acute pancreatitis < 24
hours after admission) were evaluated. In these patients EN
was initiated after a median of 3 days. This equals the stan-
dard group in the PYTHON trial. In 39% of these patients
an infection (bacteraemia, pneumonia, infected necrosis)
occurred. The mortality in the placebo arm of PROPA-
TRIA was 6%. All studies included in a meta-analysis per-
formed by our group on EN versus PN that initiated EN
within 24 hours after admission were selected [17]. In these
patients (receiving EN within 24 hours), infections were
diagnosed in 22% and mortality was 5%. Therefore, the
expected reduction in mortality is only 1%. When mortality
and infections are combined in the primary composite end-
point, an absolute reduction of 18% is expected (from 40 to
22%). With 80% power, two-sided 5% alpha and 1% loss to
follow-up the sample size was set at 208 patients [http://
www.stat.ubc.ca/~rollin/stats/ssize/b2.html].
Descriptive statistics
For dichotomous data, frequencies will be presented.
Continuous data will be presented as mean and standard
deviation or median and interquartile range. Baseline
characteristics (all prior to randomisation) are: age, sex,
body mass index, etiology of pancreatitis, American
Society of Anesthesiologists (ASA) classification, co-
morbidity (i.e. cardiovascular disease, pulmonary disease,
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chronic renal insufficiency or diabetes), predicted sever-
ity (APACHE-II, Imrie score, CRP, BUN), presence of
organ failure or multi-system organfailure, Marshall
score, amount of intravenous fluids administered prior
to randomisation, time from onset of symptoms to ran-
domisation, time from onset of symptoms to admission
and number of referrals prior to randomisation.
Analyses
All analyses will be according to the intention-to-treat
approach in which all randomised patients are included,
regardless of adherence to study protocol. After the last
patient in the trial has completed follow-up, an adjudica-
tion committee blinded for treatment allocation will evalu-
ate each patient using the raw data for the possible
occurrence of the primary endpoint. Disagreements will
be resolved in a plenary consensus meeting. Occurrences
of the primary and secondary endpoints are compared
between the treatment groups. Results are presented as
risk ratios with corresponding 95% confidence intervals.
A two-tailed P < 0.05 is considered statistically significant.
Additional analyses
To evaluate potential differences in systemic inflamma-
tory response after randomisation, the area under the
curve of APACHE-II and Marshall scores from randomi-
zation to day 7 will be calculated and compared between
treatment groups. A predefined subgroup analysis will be
done for the occurrence of the primary endpoint in
patients with an APACHE-II < 13 or an APACHE-II
≥ 13. The precise relation between the primary endpoint
and the time between start of symptoms and start of EN
will be analyzed using a generalized linear model with
logarithmic link function and Bernouilli distribution,
with independent variables time (between start of symp-
toms and start of EN), time*time, APACHE-II score prior
to randomization, hospital and co-morbidity (i.e. cardio-
vascular disease, pulmonary disease, chronic renal insuffi-
ciency or diabetes) [24].
Premature termination of the study
An interim-analysis is performed on the primary endpoint
when 50% of patients have been randomised and have
completed the 6 months follow-up. The interim-analysis is
performed by an independent statistician, blinded for the
treatment allocation. The statistician will report to the
independent DSMC. The DSMC will have unblinded
access to all data and will discuss the results of the
interim-analysis with the steering committee in a joint
meeting. The steering committee decides on the continua-
tion of the trial and will report to the central ethics com-
mittee. The Peto approach is used: the trial will be ended
using symmetric stopping boundaries at P < 0.001 [25].
The trial will not be stopped in case of futility, unless the
DSMC during the course of safety monitoring advices
otherwise. In this case DSMC will discuss potential stop-
ping for futility with the trial steering committee.
Recruiting success
The trial was registered on the 28th of February 2008 in
the ISRCTN register. The first patient was randomised
on the 17th of August 2008. So far, 142 patients have
been randomised and inclusion is ahead of schedule.
Discussion
The PYTHON trial is designed to answer the question
whether a very early start of EN will lead to a reduction
of mortality or infections in patients with predicted
severe acute pancreatitis. Over the years several strate-
gies were found ineffective in improving the outcome
for patients with severe pancreatitis [6,23,26]. The only
strategy that was consistently found to be effective in
preventing complications in patients with acute pancrea-
titis is EN [17]. This positive effect might be expanded
with the use of very early EN. In a meta-analysis of ran-
domised controlled trials in critically ill patients, a very
early start of enteral nutrition reduced the rate of infec-
tions [18]. In acute pancreatitis, timing of EN has not
been investigated in an adequately powered and well-
designed randomised trial. Therefore, the answers pro-
vided by the PYTHON trial are most needed.
Finally, the costs of EN through a feeding tube versus
an oral diet and only a feeding tube if necessary will be
compared. The extra costs of employing a feeding tube
in every patient might be compensated by an improve-
ment in outcome and subsequent reduced costs.
Rationale for design
A double-blind placebo-controlled design is generally the
preferred design for a randomised trial. In this study, this
type of design would not have been possible. In current
practice in patients with acute pancreatitis a ‘step-up’
approach is used, i.e. an oral diet is offered and only if an
oral diet is not tolerated, EN through a nasojejunal tube
is initiated. In the early EN group of this study, all
patients require a nasojejunal feeding tube to initiate
effective early enteral nutrition in the small bowel. It is
not possible to blind patients for an oral diet or a feeding
tube. It would have been possible to place a feeding tube
in all patients and to subsequently randomise between an
immediate start in the early EN group versus an oral diet
or EN after 72 hours in the control group. However, a
radiological or endoscopical placement of a nasojejunal
feeding tube is potentially aggravating for patients. In
addition, having a feeding ‘in situ’ for 72 hours (without
using it for EN), is inconvenient for patients.
To create substantial time difference between interven-
tions, a time interval of 72 hours was chosen. Perhaps a
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wider time-interval, for instance 96 hours, would have cre-
ated a larger difference between interventions. However,
in the Netherlands, a prolonged starvation period for
more than 72 hours is seldom applied and therefore not
representative for current practice [27]. The primary end-
point is a composite endpoint of mortality or infections
(bacteraemia, infected pancreatic or peripancreatic necro-
sis, pneumonia). This composite endpoint was chosen for
two reasons. If the trial would be adequately powered to
show a reduction in mortality alone, the sample size
would constitute more than 8 thousand patients. This
number of patients was not deemed feasible. In addition,
previous studies have shown that infected necrosis, pneu-
monia and bacteremia have a high impact on prognosis of
patients with acute pancreatitis [4,5].
The current design was chosen because of these meth-
odological and ethical reasons.
Conclusion
The PYTHON trial is a randomised controlled multicen-
ter trial designed to show a reduction in the composite
primary endpoint of mortality or infections following a
very early start of EN compared with a normal start of
EN in patients with predicted severe acute pancreatitis.
Additional material
Additional file 1: supplementary appendix to the PYTHON study
protocol. Supplementary file containing information on the definition of
organ failure, Marshall score, APACHE-II score, Systemic Inflammatory
Response Syndrome Criteria, Imrie score, Cost analysis and a flowchart
‘Suspicion of dislocated nasojejunal feeding tube’.
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